共 62 条
[1]
Inzucchi SE(2012)Standards of medical care in diabetes—2012 Diabetes Care 35 S11-S63
[2]
Bergenstal RM(2012)Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 55 1577-1596
[3]
Buse JB(2012)Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ 344 e1369-1238
[4]
Karagiannis T(2012)Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 35 1232-382
[5]
Paschos P(2013)Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 15 372-473
[6]
Paletas K(2013)Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 15 463-2515
[7]
Matthews DR(2013)Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial Diabetes Care 36 2508-84
[8]
Tsapas A(2013)Efficacy and safety of canagliflozin in older subjects with type 2 diabetes: a randomized trial Hosp Pract 41 72-2233
[9]
Rosenstock J(2010)Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 375 2223-2224
[10]
Aggarwal N(2013)Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial BMC Med 11 43-728